Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Research & Development (2016 - 2025)

Protalix BioTherapeutics has reported Research & Development over the past 16 years, most recently at $5.6 million for Q4 2025.

  • Quarterly results put Research & Development at $5.6 million for Q4 2025, up 36.64% from a year ago — trailing twelve months through Dec 2025 was $19.6 million (up 50.88% YoY), and the annual figure for FY2025 was $19.6 million, up 50.88%.
  • Research & Development for Q4 2025 was $5.6 million at Protalix BioTherapeutics, up from $4.5 million in the prior quarter.
  • Over the last five years, Research & Development for PLX hit a ceiling of $8.8 million in Q1 2022 and a floor of $2.9 million in Q1 2024.
  • Median Research & Development over the past 5 years was $5.6 million (2022), compared with a mean of $5.4 million.
  • Biggest five-year swings in Research & Development: crashed 50.62% in 2024 and later skyrocketed 102.36% in 2025.
  • Protalix BioTherapeutics' Research & Development stood at $7.6 million in 2021, then dropped by 26.49% to $5.6 million in 2022, then plummeted by 44.77% to $3.1 million in 2023, then soared by 32.95% to $4.1 million in 2024, then surged by 36.64% to $5.6 million in 2025.
  • The last three reported values for Research & Development were $5.6 million (Q4 2025), $4.5 million (Q3 2025), and $6.0 million (Q2 2025) per Business Quant data.